Deqi Pharmaceuticals and Pharmaceutical Biology, The whole pharmaceutical industry started cooperation to accelerate the development and production of antibody coupling drugs

In response to the clinical needs of domestic and Asia-Pacific patients, Deqi Pharmaceuticals' independent research and development and cooperation have been introduced in step, with the layout of 6 innovative early-stage research and development projects, including ADC drugs.
the research and development team continued to push forward vigorously, a number of early drugs have entered the research and development and production stage.
ADC is a complex drug produced by connecting small molecule drugs with tumor cell lethality to monoclonal antibodies through a linker, which has gradually become an emerging therapy in the field of tumor-targeted treatment with its high accuracy and remarkable therapeutic effect.
this strategic partnership, Pharmaceuticals and Pharmaceuticals will provide product intermediate scale amplification, process development and GMP production services for Deqi Pharmaceutical ADC drug development.
Among them, Dechi Pharmaceuticals focuses on the core elements of antibody coupling drugs -- the development of monoclonal antibodies;
three parties will promote the ADC drug concept through resource matching and technical complementarities to provide effective treatment for patients.
note: There are deletions in the original text